MA30689B1 - Derives de leptomycine - Google Patents
Derives de leptomycineInfo
- Publication number
- MA30689B1 MA30689B1 MA31515A MA31515A MA30689B1 MA 30689 B1 MA30689 B1 MA 30689B1 MA 31515 A MA31515 A MA 31515A MA 31515 A MA31515 A MA 31515A MA 30689 B1 MA30689 B1 MA 30689B1
- Authority
- MA
- Morocco
- Prior art keywords
- leptomycin
- leptomycin derivatives
- derivatives
- conjugates
- disulfide
- Prior art date
Links
- YACHGFWEQXFSBS-RJXCBBHPSA-N leptomycin Chemical class OC(=O)/C=C(C)/C[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)/C=C(\C)/C=C/C[C@@H](C)\C=C(/CC)\C=C\[C@@H]1OC(=O)C=C[C@@H]1C YACHGFWEQXFSBS-RJXCBBHPSA-N 0.000 title abstract 4
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 abstract 1
- 229930190887 Leptomycin Natural products 0.000 abstract 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pyrane Compounds (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE DES DÉRIVÉS DE LEPTOMYCINE COMPORTANT UN GROUPEMENT, TEL QU'UN SULFURE OU UN DISULFURE, QUI PEUVENT ÊTRE DES CONJUGUÉS D'UN RÉACTIF DE LIAISON CELLULAIRE TEL QU'UN ANTICORPS. L'INVENTION CONCERNE ÉGALEMENT LA THÉRAPEUTIQUE QUI UTILISE DE TELS CONJUGUÉS DÉRIVÉS DE LEPTOMYCINE. LESDITS CONJUGUÉS PEUVENT AVOIR UN USAGE THÉRAPEUTIQUE CAR ILS SONT SUSCEPTIBLES DE LIBÉRER DES DÉRIVÉS DE LEPTOMYCINE CYTOTOXIQUES DANS UNE POPULATION CELLULAIRE SPÉCIFIQUE SELON UN MODE CIBLÉ.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06290948A EP1864682A1 (fr) | 2006-06-09 | 2006-06-09 | Dérivés de la Leptomycine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA30689B1 true MA30689B1 (fr) | 2009-09-01 |
Family
ID=37311892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA31515A MA30689B1 (fr) | 2006-06-09 | 2008-12-26 | Derives de leptomycine |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US7816543B2 (fr) |
| EP (3) | EP1864682A1 (fr) |
| JP (1) | JP5162581B2 (fr) |
| KR (1) | KR20090018103A (fr) |
| CN (2) | CN102731611A (fr) |
| AR (1) | AR063668A1 (fr) |
| AU (1) | AU2007258896B2 (fr) |
| BR (1) | BRPI0712899A2 (fr) |
| CA (1) | CA2654322A1 (fr) |
| CL (1) | CL2007001648A1 (fr) |
| CR (1) | CR10459A (fr) |
| EA (1) | EA017345B1 (fr) |
| EC (1) | ECSP088936A (fr) |
| GT (1) | GT200800277A (fr) |
| HK (1) | HK1134240A1 (fr) |
| HN (1) | HN2008001788A (fr) |
| IL (1) | IL195419A0 (fr) |
| MA (1) | MA30689B1 (fr) |
| ME (1) | MEP88208A (fr) |
| MX (1) | MX2008015728A (fr) |
| MY (1) | MY148231A (fr) |
| NO (1) | NO20085127L (fr) |
| NZ (1) | NZ572947A (fr) |
| SG (2) | SG174066A1 (fr) |
| TN (1) | TNSN08463A1 (fr) |
| TW (1) | TWI411609B (fr) |
| UA (1) | UA95959C2 (fr) |
| WO (1) | WO2007144709A2 (fr) |
| ZA (1) | ZA200810015B (fr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1864682A1 (fr) * | 2006-06-09 | 2007-12-12 | Sanofi-Aventis | Dérivés de la Leptomycine |
| EP1914242A1 (fr) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Nouveau anticorps Anti-CD38 pour le traitement du cancer |
| CN101732308B (zh) * | 2008-11-17 | 2011-11-30 | 中国人民解放军军事医学科学院毒物药物研究所 | 来普霉素b的新用途及含有它的药物组合物和产品 |
| KR101984053B1 (ko) | 2009-02-05 | 2019-05-30 | 이뮤노젠 아이엔씨 | 신규한 벤조디아제핀 유도체 |
| FR2947269B1 (fr) | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
| FR2949469A1 (fr) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
| UY32913A (es) | 2009-10-02 | 2011-04-29 | Sanofi Aventis | Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuero |
| MX341687B (es) | 2010-02-10 | 2016-08-30 | Immunogen Inc | "anticuerpos cd20 y su utilización". |
| FR2963007B1 (fr) | 2010-07-26 | 2013-04-05 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application therapeutique |
| WO2012112708A1 (fr) | 2011-02-15 | 2012-08-23 | Immunogen, Inc. | Dérivés de benzodiazépine cytotoxiques et procédés de préparation |
| ES2939836T3 (es) | 2012-07-12 | 2023-04-27 | Hangzhou Dac Biotech Co Ltd | Conjugados de moléculas de unión celular con agentes citotóxicos |
| GB201309807D0 (en) * | 2013-05-31 | 2013-07-17 | Pharma Mar Sau | Antibody drug conjugates |
| US20150148411A1 (en) * | 2013-11-25 | 2015-05-28 | The Rockefeller University | Compositions and methods for diagnosis and therapy of disorders related to alterations of myh9 |
| CA2953371C (fr) | 2014-06-30 | 2021-08-24 | Tarveda Therapeutics, Inc. | Conjugues cibles, particules et preparations associees |
| MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
| EP3368546A4 (fr) | 2015-10-28 | 2019-06-26 | Tarveda Therapeutics, Inc. | Conjugués ciblés sstr, et ses particules et formulations |
| WO2017194568A1 (fr) | 2016-05-11 | 2017-11-16 | Sanofi | Schéma de traitement utilisant un anticorps immunoconjugué anti-muc1 à base de maytansinoïde pour le traitement des tumeurs |
| US11562115B2 (en) | 2017-01-04 | 2023-01-24 | Stmicroelectronics S.R.L. | Configurable accelerator framework including a stream switch having a plurality of unidirectional stream links |
| JOP20190254A1 (ar) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
| WO2019030284A1 (fr) * | 2017-08-09 | 2019-02-14 | Helmholtz-Zentrum für Infektionsforschung GmbH | Nouveaux dérivés de ratjadone cytotoxiques ciblés et leurs conjugués |
| US11531873B2 (en) | 2020-06-23 | 2022-12-20 | Stmicroelectronics S.R.L. | Convolution acceleration with embedded vector decompression |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4792522A (en) | 1983-12-12 | 1988-12-20 | Bristol-Myers Company | Rigolettone antitumor complex |
| US4625014A (en) | 1984-07-10 | 1986-11-25 | Dana-Farber Cancer Institute, Inc. | Cell-delivery agent |
| US4771070A (en) | 1984-08-21 | 1988-09-13 | Warner-Lambert Company | CL-1957A antibiotic compound |
| US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| US4764368A (en) | 1984-08-29 | 1988-08-16 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2076465C (fr) | 1992-03-25 | 2002-11-26 | Ravi V. J. Chari | Conjugues agents de liaison cellulaire d'analogues et de derives de cc-1065 |
| CA2380050A1 (fr) * | 1999-07-22 | 2001-02-01 | University Of Medicine And Dentistry Of New Jersey | Substances et procedes de liberation controlee d'agents therapeutiques contenant des fractions thioamide par liaison a des polymeres contenant des thiols |
| AU2001294511A1 (en) | 2000-06-30 | 2002-01-08 | The Regents Of The University Of California | New strategy for leukemia therapy |
| US20030091640A1 (en) * | 2001-02-08 | 2003-05-15 | Srinivasan Ramanathan | Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents |
| ES2539627T3 (es) | 2002-11-07 | 2015-07-02 | Immunogen, Inc. | Anticuerpos anti-CD33 y método para el tratamiento de leucemia mieloide aguda usando los mismos |
| AU2005249490B2 (en) * | 2004-06-01 | 2010-07-29 | Genentech, Inc. | Antibody drug conjugates and methods |
| US7446196B2 (en) * | 2004-06-03 | 2008-11-04 | Kosan Biosciences, Incorporated | Leptomycin compounds |
| US7541330B2 (en) * | 2004-06-15 | 2009-06-02 | Kosan Biosciences Incorporated | Conjugates with reduced adverse systemic effects |
| WO2006135371A1 (fr) * | 2005-06-09 | 2006-12-21 | Kosan Biosciences Incorporated | Conjugués à effets adverses systémiques réduits |
| EP1864682A1 (fr) * | 2006-06-09 | 2007-12-12 | Sanofi-Aventis | Dérivés de la Leptomycine |
-
2006
- 2006-06-09 EP EP06290948A patent/EP1864682A1/fr not_active Withdrawn
-
2007
- 2007-05-23 UA UAA200900137A patent/UA95959C2/ru unknown
- 2007-05-23 JP JP2009513781A patent/JP5162581B2/ja not_active Expired - Fee Related
- 2007-05-23 EP EP11188684A patent/EP2540320A1/fr not_active Withdrawn
- 2007-05-23 WO PCT/IB2007/001328 patent/WO2007144709A2/fr active Search and Examination
- 2007-05-23 BR BRPI0712899-1A patent/BRPI0712899A2/pt not_active IP Right Cessation
- 2007-05-23 CA CA002654322A patent/CA2654322A1/fr not_active Abandoned
- 2007-05-23 MY MYPI20084971A patent/MY148231A/en unknown
- 2007-05-23 KR KR1020087029913A patent/KR20090018103A/ko active IP Right Grant
- 2007-05-23 NZ NZ572947A patent/NZ572947A/en not_active IP Right Cessation
- 2007-05-23 SG SG2011057809A patent/SG174066A1/en unknown
- 2007-05-23 CN CN2012102164755A patent/CN102731611A/zh active Pending
- 2007-05-23 SG SG2011057817A patent/SG174067A1/en unknown
- 2007-05-23 EP EP07734635A patent/EP2032172B1/fr active Active
- 2007-05-23 ME MEP-882/08A patent/MEP88208A/xx unknown
- 2007-05-23 EA EA200870615A patent/EA017345B1/ru not_active IP Right Cessation
- 2007-05-23 MX MX2008015728A patent/MX2008015728A/es active IP Right Grant
- 2007-05-23 AU AU2007258896A patent/AU2007258896B2/en not_active Ceased
- 2007-05-23 CN CN2007800215355A patent/CN101466409B/zh not_active Expired - Fee Related
- 2007-05-24 TW TW096118553A patent/TWI411609B/zh not_active IP Right Cessation
- 2007-06-07 CL CL2007001648A patent/CL2007001648A1/es unknown
- 2007-06-08 AR ARP070102511A patent/AR063668A1/es not_active Application Discontinuation
-
2008
- 2008-11-17 TN TNP2008000463A patent/TNSN08463A1/en unknown
- 2008-11-20 IL IL195419A patent/IL195419A0/en unknown
- 2008-11-24 US US12/276,568 patent/US7816543B2/en not_active Expired - Fee Related
- 2008-11-25 CR CR10459A patent/CR10459A/es not_active Application Discontinuation
- 2008-11-25 ZA ZA2008/10015A patent/ZA200810015B/en unknown
- 2008-12-03 EC EC2008008936A patent/ECSP088936A/es unknown
- 2008-12-08 GT GT200800277A patent/GT200800277A/es unknown
- 2008-12-09 NO NO20085127A patent/NO20085127L/no not_active Application Discontinuation
- 2008-12-09 HN HN2008001788A patent/HN2008001788A/es unknown
- 2008-12-26 MA MA31515A patent/MA30689B1/fr unknown
-
2009
- 2009-12-10 HK HK09111635.9A patent/HK1134240A1/xx not_active IP Right Cessation
-
2010
- 2010-09-14 US US12/881,792 patent/US20110002947A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA30689B1 (fr) | Derives de leptomycine | |
| MA32099B1 (fr) | Composition comprenant un anticorps se liant au domaine ii de her2 et variantes acides de celle-ci | |
| MA29975B1 (fr) | Antagonistes de la neuropiline | |
| TNSN07398A1 (fr) | Anticorps contre la p-cadherine | |
| WO2006114308A8 (fr) | Porteur destine a cibler des cellules nerveuses | |
| MA29369B1 (fr) | Dosage fixe d'anticorps anti-her | |
| MA35345B1 (fr) | Proteines de liaisons a un antigene ayant une liaison accrue a fcrn | |
| MA30910B1 (fr) | Anticorps et immunoconjugues, et leurs utilisations | |
| MA30557B1 (fr) | Composés de pyrrolopyrimidine et leurs utilisations. | |
| NZ553701A (en) | Composition comprising SC03-014 and SC03-022 antibodies against SARS-CoV | |
| MA31617B1 (fr) | Agents cytotoxiques comprenant de nouveaux dérivés de la tomaymycine et leur utilisation thérapeutique. | |
| MA30345B1 (fr) | Formulation d'anticorps monoclonal humain anti-igf-1r | |
| MA29243B1 (fr) | Agonistes de pyy et leurs utilisations | |
| ATE246517T1 (de) | Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung | |
| WO2000056774A8 (fr) | Procede d'utilisation de bioelastomeres | |
| WO2007067597A3 (fr) | Procedes et compositions d'apport sans aiguille de partenaires de liaison | |
| MA30337B1 (fr) | Anticorps | |
| MA30653B1 (fr) | Anticorps monoclonaux anti-il-6 et leurs utilisations | |
| CR8093A (es) | Composicion de farmaco conjugado | |
| WO2003059251A3 (fr) | Composes de ciblage d'anticorps | |
| EP2316847A3 (fr) | Toxines clostridiennes modifiées dotées de capacités de ciblage améliorées pour systèmes récepteurs de la toxine clostridienne | |
| WO2006104989A3 (fr) | Anticorps a regions fc modifiees et utilisations | |
| RS53168B (en) | Antibodies and Immunoconjugates and Their Use | |
| WO2007030577A3 (fr) | Promedicaments de t3 et de t4 presentant une biodisponibilite accrue | |
| MX2009006410A (es) | Conjugados de polimero-oligonucleotido, proteina y/o peptido. |